Ehud Bendory

Evergreen Venture Partners Ltd (Evergreen Ventures) is a venture capital firm founded in 1987 by Jacob Burak and Ofer Neeman. The firm is headquartered in Tel Aviv, Israel.

Gnx Data Systems, Inc. develops and operates big data platform for analyzing and managing genetic data in the cloud. It specializes in bioinformatics, genomic analysis, genome interpretation, precision medicine, clinical trial matching, variant assessment, rare disease analysis and prenatal examination. The company was founded Moshe Einhorn and Amir Trabelsi in 2014 and is headquartered in Palo Alto, CA.

Hadassah, The Women's Zionist Organization of America, Inc. provides health and medical support services. It offers health and medicine in hospitals, trauma care, medical research, cardiac care, and breast cancer. The company was founded by Henrietta Szold in 1912 and is headquartered in New York, NY.

Ethos Ventures ( Ethos VC) is a venture capital firm founded in 2020. The firm is headquartered in San Francisco, California.

RedDress USA, Inc. specializes in providing advanced wound care products and skin substitutes for the treatment of chronic wounds. The company is based in Ponte Vedra Beach, FL. The company's ActiGraft Virtual Training program offers comprehensive training for healthcare providers to begin offering ActiGraft within their healthcare setting. The company was founded in 2009 by Igal Kushnir and Alon Kushnir, with Alon Kushnir serving as the CEO since 2009.

Peer Medical, Inc. is a company that allows cancer patients to share and compare their treatment experiences with other survivors. The company is based in San Francisco, CA and was founded by Ed Spiegel. The company uses electronic medical records to verify users and organize the data, making it easier for patients to find the most relevant information for their care.

Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel.

Ares-Serono Group is a Swiss pharmaceutical company that manufactures and wholesales pharmaceutical products. The private company is based in Geneva, Switzerland. and has subsidiaries in Ecuador.

Part of Merck KGaA, Interpharm Laboratories Ltd. is an Israeli company that develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. The company is based in Rehovot, Israel. The company was founded by Israel Makov.

Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.